B Cells, Cytokines,
and Systemic Lupus
Erythematosus:
Exploring New
Therapeutic Strategies
Complimentary Lunch Symposium
1:00 pm - 3:15 pm
Wednesday, October 21, 2009
Loews Philadelphia Hotel
Philadelphia, Pennsylvania
| This symposium will be conducted during the 2009 ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY |
Description
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease with no specific cause or cure. An estimated 300,000 Americans suffer from various forms of lupus, including SLE. In the past two decades, the medical understanding of the molecular and cellular basis of SLE pathogenesis has undergone substantial advances, which have accelerated in recent years.
Advances in B-cell biology have permitted the development of new therapeutic strategies in SLE based on targeting both celluler and humoral factors. Among these targets are those found on B cells and accessory cells essential for B-cell maturation growth and differentiation leading to autoantibody formation and immune mediated tissue damage.
In addition, advances in cytokine biology, including elucidation of the B-cell stimulatory factor-related family of B-cell centric factors, have spurred development of a number of biologic agents, which are in varying stages of clinical development.
This symposium is designed to provide an evidence-based review of research on B-cell pathogenesis in SLE and developments in B-cell targeted therapies for SLE, with the overall goal of improving outcomes in this patient population.
GOING GREENElectronic Syllabus: Syllabus will only be provided to registrants on a USB flash drive. Attendees are encouraged to bring their laptops to the symposium to view the syllabus. |
Target Audience
The symposium is intended for rheumatologists, rheumatology fellows, and other interested healthcare professionals.
Objectives
Upon completion of this symposium, the participant will be able to:
- Describe the process of B-cell development and censoring of autoreactivity as it applies to the pathogenesis of autoimmunity and SLE;
- Describe the rationale and appraise the results from strategies targeting cellular elements in the humoral immune response in SLE;
- Appraise the results of human trials targeting B-cell survival signals in SLE.
Faculty
| Activity Directors |
| Leonard H. Calabrese, DO Professor of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University RJ Fasenmyer Chair of Clinical Immunology Vice Chairman, Department of Rheumatic and Immunologic Dieseases Orthopaedic & Rheumatologic Institute Cleveland Clinic Cleveland, Ohio |
| Gregg J. Silverman, MD Professor of Medicine Director, Laboratory of B Cell Immunology Division of Rheumatology, Allergy, and Immunology University of California, San Diego School of Medicine La Jolla, California |
| Faculty |
| Jennifer H. Anolik, MD, PhD Associate Professor of Medicine Division of Allergy, Immunology and Rheumatology University of Rochester Medical Center Rochester, New York |
| Joan T. Merrill, MD Member and Program Chair, Clinical Pharmacology Research Program Oklahoma Medical Research Foundation OMRF Professor of Medicine University of Oklahoma Medical Center Medical Director, Lupus Foundation of America Oklahoma City, Oklahoma |
Agenda
| WEDNESDAY, OCTOBER 21, 2009 | |
| 1:00 pm | Registration / Lunch |
| 1:30 pm | Introduction: Progress and Problems in SLE Therapeutic Research - Leonard H. Calabrese, DO |
| 1:40 pm | The Role of B Cell Development in the Pathogenesis of Autoimmunity and SLE - Jennifer H. Anolik, MD, PhD |
| 2:05 pm | Clinical Strategies of B Cell Targeting in SLE: A Cellular Approach from Bench to Bedside - Gregg J. Silverman, MD |
| 2:30 pm | Clinical Strategies for B Cell Targeting in SLE: Soluble Factors as Target - Joan T. Merrill, MD |
| 2:55 pm | Questions / Panel Discussion |
| 3:15 pm | Adjourn |
Location
| Loews Philadelphia Hotel 1200 Market Street Philadelphia, Pennsylvania 19107 215-627-1200 |
|
| Click here for the Google Map location |
Additional Information
For further information about this symposium, contact UNITECH Communications® at:
Local: 216-448-0770
Toll Free: 800-238-6750
For questions about registering online, call 216-448-0777 or email CMEregistration@ccf.org.
Faculty Disclosure
The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.
Americans with Disabilities Act
The Cleveland Clinic Foundation Center for Continuing Education fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify UNITECH Communications® at 216-448-0770 or 800-238-6750 at least two weeks prior to the activity.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Online Registration/Fees
Registration fee includes electronic syllabus and lunch.
| Category | Full Course |
|---|---|
| All Attendees | Complimentary |
